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RLimitations of Gait Speed as
an Independent Predictor of
Mortality and Morbidity in
Cardiac Patients
Afilalo et al. (1) report that an impaired gait speed (a simple
measure of frailty) can be used to identify elderly patients at high
risk of major in-hospital events after cardiac surgery. They defined
the primary predictor slow gait speed as the time taken to walk 5 m
in more than 6 s.
Gait speed is already an established marker of exercise capacity
in the elderly (2), and thus the results of the study are not
surprising. The overwhelming amount of previous studies includ-
ing statements of consensus definitions for sarcopenia and cachexia
in elderly and in chronically ill patients defines slow gait speed as
a walking speed 0.8 m/s on the 4-m walk test (3,4). We thus
ere surprised to see that Afilalo et al. (1) used a different
efinition of slow gait speed and suggest using a 5-m walk test. For
he 4-m gait speed test, a very large body of population-based data
nd normal values are available (from investigations in many
housands of subjects [4]). To reinvent the wheel may sometimes
e a good idea, but it seems that this is not such an occasion,
articularly not if we want our studies to be accepted outside of
ardiology by general medicine and geriatrics; after all many of our
atients are elderly. Afilalo et al. (1) suggest that a time of 6 s to
alk 5 m is “normal” (i.e., 0.833 m/s), but where is the evidence
f this? This small study with 131 patients cannot establish
normality.” Very large population-based studies found a cutoff of
.8 m/s (3). We in cardiology should use these cutoffs as well, at
east until we have proved that they are not useful in our patients
which seems doubtful). We suggest focusing on the use of the
revious and established definition for the 4-m walk test in future
rials. This would allow better comparability between previous,
ngoing, and future studies in the field of frailty, sarcopenia,
nd/or cachexia in patients with heart disease as well as other
hronic illnesses.
Regarding the survival analysis, we only want to state that
ccording to their Table 1, it appears that many important
arameters known to affect prognosis of such patients (including
nemia, estimated glomerular filtration rate, body temperature,
nd plasma levels of natriuretic peptides) were not considered.
ence, we find the statement that gait speed (regardless of how it
s measured) is an “incremental predictor of mortality and major
orbidity” in elderly patients undergoing cardiac surgery too broad
nd likely wrong in selected patients. We believe that the value of
sing slow gait speed as a reliable marker for surgical or other
utcomes in patients with cardiac illness still needs to be better
efined.
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Reply
We appreciate the interest of Dr. Thum and colleagues in our
prospective study of gait speed in elderly patients undergoing
cardiac surgery (1). Two points are raised: the first concerns the
validity of the gait speed protocol used, and the second concerns
the selection of the covariates evaluated in the multivariable model.
First, the gait speed protocol used in this study was prespecified
to be a 5-m distance with a cutoff fit to optimally predict the
occurrence of mortality or major morbidity in our patient popula-
tion (which was 6 s [0.83 m/s] as determined by receiver-operating
characteristic analysis). Dr. Thum and colleagues suggest that this
distance and cutoff are not consistent with consensus definitions.
We respectfully disagree and point to the recent task force position
statement on gait speed that highlights a variety of distances and
cutoffs appropriately used in the medical literature (2). Accord-
ingly, the most common distances were between 4 and 6 m, and
the most common cutoffs were between 0.6 and 1.0 m/s, depend-
ing on the patient population being evaluated and the outcome
being predicted. The task force authors go on to state that “the use
of gait speed at usual pace as a predictor makes the course-distance
of less importance.” In keeping with this, Graham et al. (3)
demonstrated that course distance was not a significant determi-
nant of mean gait speed. Therefore, although a 4-m, 0.8-m/s
protocol is endorsed by some, there remains justified variability and
the 5-m, 6-s protocol used in this study is entirely within
evidence-based standards. Moreover, we find it important to
correct that short-distance gait speed is not intended to be a
marker of exercise capacity nor of sarcopenia and cachexia, as
suggested, but rather a marker of frailty, which is regarded as a
distinct entity.
Second, the covariates evaluated in the multivariable model
were prespecified to be the Society of Thoracic Surgeons predicted
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August 9, 2011:775–8risk of mortality or major morbidity and a group of 7 individual
risk factors that had been shown to account for the bulk of the
outcomes observed. It is undoubtedly true that other risk factors
exist; however, the benefit of adding covariates in a statistical
model must be weighed against the risk of overfitting and
detecting spurious associations (4). In light of this, we, like many
others, opted for a parsimonious model containing core risk factors
rather than exhaustive ones.
Good clinical practice dictates that the incorporation of new
tests and treatments should be based on sound evidence, ideally
from more than a single study. As stated in our paper, we
wholeheartedly endorse and look forward to future efforts to study
the optimal cutoff for slow gait speed and to validate the role of gait
speed as a prognostic marker in patients undergoing cardiac
surgery.
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Valve Academic Research
Consortium Consensus Report
The Pharmaceutical and
Medical Devices Agency Perspective
First, we sincerely express our appreciation for the organized effort
by the Valve Academic Research Consortium (VARC) members(1). Similar to the United States, there is no approved transcatheter
aortic valve implantation (TAVI) device in Japan at present. We
believe that this VARC consensus report is beneficial, even for the
Pharmaceutical and Medical Devices Agency (PMDA), which is
the regulatory authority in Japan.
Although we believe that the consensus is already well orga-
nized, we comment here on several points from the PMDA
perspective.
1. The definition of intended performance of the prosthetic heart
valve. Considering implantation in smaller body size, such as in
Asian patients, or future possible expansion of the size variation of
TAVI device, the critical value of 1.2 cm2 for the aortic valve area
ay need some adjustment based on patient body size or device
ize.
. Hospitalization criteria variance among countries. We bring to
our attention that there will be a possible bias by each country’s
edical care setting. For example, the threshold of hospitalization
ould be lower in Japan than in United States or the European
nion.
. Evaluation of stroke. The consensus proposed the modified
ankin Scale (mRS) score at 30 and 90 days for the stroke
efinition. We suggest that National Institutes of Health Stroke
cale (NIHSS) should also be used, and the time point of the
valuations should cover event onset (acute phase) as well, first,
ecause generally the mRS score would be appropriate for the
elatively chronic phase and NIHSS would be more appropriate for
he acute phase and, second, because immediate treatment of
troke will greatly influence the mRS score at 30 and 90 days, and
ts evaluation would not properly reflect the impact as a TAVI
omplication. In addition, the NIHSS was proposed in U.S. Food
nd Drug Administration guidelines (2) in 2007 for a neurothrom-
ectomy device and used in many clinical studies for cerebrovas-
ular disorders.
We hope that our comments contribute to honing the criteria
onsensus further.
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